ADAMTS13, recombinant (Adzynma)
Revision as of 23:51, 14 May 2024 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== Replacement therapy ==Diseases for which it is established== *Congenital thrombotic thrombocytopenic purpura ==Diseases for which it is used== *[...")
Mechanism of action
Replacement therapy
Diseases for which it is established
Diseases for which it is used
History of changes in FDA indication
- 2023-11-09: Approved for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).
Also known as
- Brand name: Adzynma